Neurogene (NGNE) CCO granted 120,000 non-qualified stock options at $28.94

Rhea-AI Filing Summary

Neurogene Inc. reported that Chief Commercial Officer Christina Shafer received a grant of non-qualified stock options covering 120,000 shares of common stock at an exercise price of $28.94 per share. One quarter of these options will vest on April 20, 2027, with the remaining three quarters vesting in equal monthly installments on the 20th of each month through April 20, 2030, contingent on her continued service. Following this grant, she holds 120,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shafer Christina

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	120,000	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 120,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 120,000 options Exercise price: $28.94 per share Underlying shares: 120,000 shares +4 more

7 metrics

Options granted 120,000 options Non-qualified stock option grant to CCO on May 5, 2026

Exercise price $28.94 per share Exercise price for 120,000 Neurogene options

Underlying shares 120,000 shares Common stock underlying the option grant

Post-grant derivative holdings 120,000 options Total derivative securities held directly after grant

Initial vesting date April 20, 2027 One quarter of options vest on this date

Final vesting date April 20, 2030 Remaining options vest monthly through this date

Expiration date May 5, 2036 Option term end for this grant

Key Terms

Non-Qualified Stock Option, vest, exercise price, expiration date

4 terms

Non-Qualified Stock Option financial

"This option represents the right to purchase 120,000 shares of the Issuer's common stock"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

vest financial

"one quarter of which will vest on April 20, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: 28.9400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-05T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shafer Christina

(Last) (First) (Middle)

535 W 24TH STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neurogene Inc. [ NGNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$28.94	05/05/2026		A		120,000		(1)	05/05/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

Remarks:

	Donna M. Cochener, Attorney-in-Fact for Christina Shafer	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neurogene (NGNE) report for Christina Shafer?

Neurogene reported that Chief Commercial Officer Christina Shafer received a grant of 120,000 non-qualified stock options. These options give her the right to buy Neurogene common stock at a fixed exercise price of $28.94 per share if and when they vest.

What is the vesting schedule for Christina Shafer’s 120,000 NGNE stock options?

One quarter of the 120,000 options will vest on April 20, 2027. The remaining three quarters vest in equal monthly installments on the 20th of each month through April 20, 2030, conditioned on Ms. Shafer’s continued service with Neurogene.

What is the exercise price and expiration date of Christina Shafer’s NGNE options?

The granted options carry an exercise price of $28.94 per share. They are scheduled to expire on May 5, 2036, if not exercised earlier, giving a long time window during which vested options may potentially be exercised under the plan’s terms.

How many Neurogene derivative securities does Christina Shafer hold after this grant?

After this transaction, Ms. Shafer directly holds 120,000 derivative securities in the form of non-qualified stock options. These options relate to an equivalent number of Neurogene common shares, subject to the vesting schedule and the $28.94 exercise price described.

Is Christina Shafer’s Form 4 transaction a purchase or a compensation grant of NGNE options?

The Form 4 reflects a grant/award acquisition of non-qualified stock options, not an open-market purchase or sale. The options were awarded at an exercise price of $28.94 per share, with vesting over time, as part of her compensation arrangement.